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Abstract
Aims—To determine how variable stool consistency is in patients with irritable bowel (IBS) and
assess the relationship between stool consistency and gastrointestinal symptoms.
Methods—Individuals with a physician diagnosis of IBS were recruited by advertisement.
Enrollment questionnaires included the Rome III Diagnostic Questionnaire and IBS Symptom
Severity Scale. Then 185 patients meeting Rome criteria for IBS rated the consistency (using the
Bristol Stool Scale) of each bowel movement (BM) for 90 days and whether the BM was
accompanied by pain, urgency, or soiling. Each night they transferred BM ratings from a paper
diary to an internet form and also reported the average daily intensity of abdominal pain, bloating,
bowel habit dissatisfaction, and life interference of bowel symptoms. Only the longest sequence of
consecutive days of diary data was used in analysis (average of 73 days).
Results—Patients were 89% female with average age 36.6 years. 78% had both loose/watery and
hard/lumpy stools; the average was 3 fluctuations between these extremes per month. The
proportion of loose/watery stools correlated r=.78 between the first and second months and the
proportion of hard/lumpy stools correlated r=.85 between months. Loose/watery stools were
associated with more BM-related pain, urgency, and soiling than hard/lumpy or normal stools;
however, IBS-C patients had significantly more BM-unrelated abdominal pain, bloating,
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dissatisfaction with bowel habits, and life interference than IBS-D. Questionnaires overestimated
the frequency of abnormal stool consistency and gastrointestinal symptoms compared to diaries.
Conclusions—Stool consistency varies greatly within individuals. However, stool patterns are
stable within an individual from month to month. The paradoxical findings of greater symptom
severity after individual loose/watery BMs vs. greater overall symptom severity in IBS-C implies
different physiological mechanisms for symptoms in constipation compared to diarrhea. Daily
symptom monitoring is more sensitive and reliable than a questionnaire.
Introduction
Patients with irritable bowel syndrome (IBS) are subtyped into those with predominant
diarrhea (IBS-D), predominant constipation (IBS-C), mixed or alternating bowel habits
(IBS-M), and those with no significant abnormalities in their stools (IBS-U)1. The
assignment of IBS patients to the appropriate subtype is critical to management because
pharmacological treatments for IBS are designed to address either constipation or diarrhea
as a means of improving the multiple symptoms of IBS. Lubiprostone2, linaclotide3, and
tegaserod4 were developed to treat IBS-C whereas alosetron5 was developed to treat IBS-D,
and the use of these drugs in a subtype of IBS different from the one it was developed for is
thought to place the patient at risk for worsening bowel symptoms. Thus it is important to
know whether patients can be reliably classified into these subtypes and whether the
subtypes are stable over time.
Previous studies suggest, however, that IBS subtype classification is not stable: half6 to ¾ of
IBS patients7, 8 change their subtype classification over a one-year period. Most of these
transitions are between IBS-C and IBS-M or between IBS-D and IBS-M, with relatively few
patients transitioning between IBS-D and IBS-C7. This degree of instability raises concerns
about the reliability of treatment guidelines based on IBS subtype and suggests that more
data is needed on within-subject variability in stool consistency and the relationship between
variations in stool consistency and other symptoms of IBS such as pain and bloating.
Limited data are available on the relationship of stool consistency to other IBS symptoms,
and the findings are often inconsistent. Hellstrom et al9 reported that pain episodes are more
closely associated with loose/watery stools than with hard/lumpy stools, although
Ragnarsson10 found no relationship between abdominal pain and defecation. Chang et al11
reported that abdominal distention is more strongly associated with IBS-C than with IBS-D
whereas the subjective sensation of bloating without distention is more closely associated
with diarrhea; they found that defecation or passing gas relieved both bloating and
distention. Other investigators, however, find no association between bowel habits and
either distention or bloating12. Urgency is more closely associated with diarrhea than with
constipation13.
The primary aims of this 90-day diary study were to (1) characterize the bowel-movement-
to-bowel movement and day-to-day variability in stool consistency for IBS patients and (2)
describe the association of abnormal stool consistency and IBS subtype with other
gastrointestinal symptoms and the interference of abnormal stool consistency in the patient's
life. A secondary aim was to determine whether the Rome III classification of IBS patients
into IBS-C, IBS-M, and IBS-D subtypes by retrospective questions is confirmed by
prospective diary data.
Methods
Individuals with IBS aged18 years and older were enrolled through advertising to complete
90 days of diary recordings of their bowel movements and gastrointestinal symptoms. The
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study was advertised on the website of the Center for Functional GI & Motility Disorders at
UNC-Chapel Hill, on national websites frequented by IBS patients (such as IFFGD.org and
IBSgroup.org), and through mass e-mails to staff, students and faculty at UNC-Chapel Hill.
Additionally, IBS patients who had registered to participate in research studies in our Center
were invited to participate.
Inclusion criteria in the study were age of at least 18 years (no upper limit), daily access to
the internet, fulfilling Rome III criteria for IBS1, and having been diagnosed with IBS by a
physician. Exclusion criteria were a history of inflammatory bowel disease, celiac disease or
lactose intolerance, daily use of IBS prescription medications (lubiprostone, tegaserod or
alosetron), and current participation in pharmacologic trials. Subjects were permitted to use
anti-diarrheal or laxative medications or antidepressants occasionally, but were asked to
refrain from using these drugs as much as possible during the study and to record when they
used them in their symptom diary.
A total of 595 potential subjects were screened online for participation in the study, out of
which 392 met study criteria and were invited to enroll through the mail. The mailing
contained (1) the study consent form and a physician release of information form for
verifying IBS diagnosis, both of which the subjects were instructed to sign and return via
mail; (2) the printed pocket diary for recording bowel movements and associated symptoms;
and (3) instructions and a password for accessing the secure study website to enter study
data.
Before beginning to record their bowel symptoms in the diary, subjects completed the Rome
III Diagnostic Questionnaire14, the IBS Severity Scale (IBS-SS)15, the IBS Quality of Life
questionnaire (IBS-QOL)16, 17, and the Brief Symptom Inventory 18 (BSI-18)18which is a
psychological symptom questionnaire.
The Rome III Diagnostic Questionnaire14 includes two questions that are used to determine
IBS subtype. One question asks, “In the last 3 months, how often did you have hard or
lumpy stools?” and the other asks, “In the last 3 months, how often did you have loose,
mushy, or watery stools?” The standard response choices are 0 = “Never or rarely”; 1=
“Sometimes”; 2= “Often”, 3= “Most of the time”; and 4= “Always”; although investigators
are given the option of substituting a different response scale in which 0= “Never or rarely”;
1= “About 25% of the time”; 2= “About 50% of the time”; 3=“About 75% of the time”; and
4= “Always, 100% of the time”. In this study the standard response scale was used and a
response of “Sometimes” was treated as equivalent to 25% of BMs.
The IBS-SS questionnaire15 consists of 5 equally weighted questions about IBS symptoms
in the last 10 days. The average severity of abdominal pain, average severity of bloating,
dissatisfaction with bowel habits, and interference of symptoms with activities of daily life
are queried on 0-100 mm visual analog scales. A fifth question asks about the number of
days of abdominal pain in the last 10 days, and the response is multiplied by 10 to give this
question the same weight as the other 4.
After completing these baseline questionnaires, subjects began the 90-day diary recording
period in which they reported on every bowel movement (BM) throughout each day in a
pocket-sized diary notebook. They rated the stool consistency of each BM on the 7-point
Bristol Stool Scale19 by referring to pictures and verbal descriptors in their diary book, and
reported (yes/no) any associated symptoms of urgency, pain, or fecal soiling. Each night, the
subjects were asked to transfer their diary ratings for that day to a secure website, where
they also rated on a 0-10 scale their global 24-hour symptoms of abdominal pain, bloating,
dissatisfaction with their BMs, and life interference from bowel symptoms (the same
symptoms included in the IBS-SS15 questionnaire), and life stress. They were also asked to
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report any medications used during the day. If subjects failed to complete the online diary on
any given day, they were reminded to do so by study staff the next day via e-mail. They
could then enter their data for the previous day, but were only allowed to enter data for one
retrospective day. If subjects missed more than three days of diary recordings, their
participation was terminated.
The study participants were paid one dollar for each diary day they completed to
compensate them for their time and effort, and they also received an additional bonus of $30
for every 30 days of the total 90-day diary period that they completed without interruptions.
The study was reviewed and approved by the Biomedical Institutional Review Board at the
University of North Carolina at Chapel Hill.
Data Analysis
Data from all subjects who completed a minimum continuous diary record period of at least
21 days were analyzed. This resulted in an analysis sample of 185 patients. For each patient
record analyzed, only the single longest continuous stretch of diary days was selected for
analysis; i.e., no interrupted date sequences were used in the analyses. The average length of
the continuous diary records submitted to analysis was 72.9 days (median 86 days, range
21-106 days; a few subjects continued diary data entry longer than the required 90 days).
The diary periods analyzed contained an average of 133.2 consecutive BMs.
To characterize bowel-movement-to-bowel-movement and day-to-day variability in stool
consistency (Aim 1), we calculated the proportion of BMs and days with each stool
consistency in the whole group of 185 IBS patients. To address the secondary aim –
validation of the Rome classification of IBS patients into subtypes – we compared the IBS-
subtypes assigned based on the diary data to the subtypes based on the Rome III Diagnostic
Questionnaire completed at enrollment. In both cases, patients were classified as IBS-D if
they had >25% loose/watery BMS and <25% hard/lumpy BMS; IBS-C if they had <25%
loose/watery BMs and >25% hard/lumpy BMs; IBS-M if they had >25% loose/watery BMs
and >25% hard/lumpy BMs; and IBS-U if they had <25% loose/watery and <25% hard/
lumpy BMs. Patients who took laxatives or antidiarrheal medications were excluded from
this analysis. To investigate the relationship between stool consistency and gastrointestinal
symptoms such as pain and bloating, we first examined the associations between these
symptoms and stool types in the pooled sample of all 185 IBS patients. Next we compared
symptom severity in IBS subtypes defined by the Rome III Diagnostic Questionnaire.
A separate analysis was performed to assess the stability of bowel habits and IBS symptoms
by comparing the first and second 30-day periods of diary records for the same subject. This
analysis was limited to the 135 subjects who had at least 60 days of uninterrupted diary
entries. For this analysis the IBS-SS index was computed based on the diary data as follows:
for daily questions on abdominal pain severity, bloating severity, dissatisfaction with bowel
habits, and interference with activities of daily life, the average severity score for the 30 day
period was used in the computation of the IBS-SS, and the proportion of days with any pain
was multiplied by 100.
Two post-hoc analyses were performed to follow up on the paradoxical finding that on
average, IBS-C patients had more severe symptoms of pain, bloating, bowel habit
dissatisfaction, and life interference than IBS-D patients, although when individual BMs
were compared to each other, loose/watery stools triggered more intense symptoms than
hard/lumpy or normal consistency stools. The first analysis was an ANOVA comparing IBS-
subtypes on days without any BM, and the second analysis compared pain and bloating by
paired t-tests on cumulative days of constipation (hard/lumpy stools or no BM) for patients
with IBS-C.
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Chi-square tests were used to compare subgroups on categorical variables. Analysis of
variance tests with Bonferroni-adjusted post-hoc tests were used to compare mean scores on
continuous variables between and within subgroups. Correlations between variables were
assessed by the Spearman nonparametric correlation coefficient.
Results
Subject characteristics
Of the 392 subjects who met inclusion criteria and were invited to participate in the study,
206 (52.5%) enrolled and started diary entries. Non-participants were not significantly
different from participants with respect to age, sex, or frequency of self-reported bowel
symptoms (abdominal pain, loose/watery stools or hard/lumpy stools in the past 3 months)
on screening questionnaires. Seven enrolled subjects dropped out after beginning the diary
recordings, and 5 others were dismissed due to low compliance with diary entries. Another 9
subjects completed the 3-month study but were not included in the data analysis because
their diary records did not meet the criterion of 21 consecutive days of complete data.
Average age of the 185 patients included in the analyses for this study was 36.6 years (range
19 to 70). The sample was 88.6% females (164/185). The Rome III IBS subtype distribution
based on the Rome III Diagnostic Questionnaire18 was 31.9% IBS-D, 55.1% IBS-M, and
12.4% IBS-C. Only one subject (0.5%) had IBS-U. Self-described races of participants were
94.1% Caucasian, 2.7% African-American, 0.5% Asian, and 2.7% mixed race. Age and race
were equivalent between bowel subtype groups (Table 1), but sex distribution was not (Chi-
square=0.007): the IBS-D subgroup had a higher proportion of males than IBS-C or IBS-M.
The average IBS Severity Score on retrospective questionnaires completed at enrollment
was 248.6, which is in the moderate range according to published guidelines for this scale15:
23.2% had scores in the mild range (≤175), 42.7% in the moderate range (>175 and <300)
and 34.1% in the severe range (≥300). The IBS-D, IBS-M and IBS-C subgroups had
equivalent mean scores both on overall IBS severity and the individual bowel symptoms
measured by the IBS-SS at screening, and they did not differ significantly either in quality
of life, psychological distress or life stress ratings (Table 1).
Medication use
Of the total analysis sample of 185 individuals, 28 (15.1%) used anti-diarrheal medications
during the study, 25 (13.5%) used laxatives, and 2 (1.1%) used both. Eleven subjects
reported using antidepressants at least once but 45 did not respond to this question. One
hundred thirty subjects (70.3%) used neither laxatives nor anti-diarrheal medications during
the diary recording period.
Distribution of Stool Consistency Ratings across Bowel Movements
In the total sample of 185 IBS patients, the majority (58.1%) of BMs received Bristol Stool
Scale ratings of 3-5 which define the normal range. Loose/watery stools and hard/lumpy
stools were about equally represented (20.5% and 21.2% respectively). Average stool
frequency was 1.80 per day.
To ensure that the use of laxatives or anti-diarrheal medications by 30% of the patients in
the study did not bias this general characterization of stool consistency patterns in IBS, we
repeated the analysis of stool consistency ratings across BMs after excluding all patients
who reported using anti-diarrheal medications or laxatives. This changed the results very
little: 59.3% of BMs were of normal consistency, 20.4% were loose/watery and 20.3% were
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hard/lumpy. Average stool frequency was 1.79 BMs/day in those taking no laxatives or
antidiarrheal medications.
Fluctuations between loose/watery stools (Bristol Stool Scores of 6 or 7) and hard/lumpy
stools (Bristol Stool Scores of 1 or 2) were common even among patients who took no
laxatives or antidiarrheal medications. In this group of 130 individuals, only 13 (10%) had
no loose/watery stools in their diary records, and only 17 (13.1%) had no hard/lumpy stools.
Fluctuations between loose/watery and hard/lumpy stools occurred in 77.7% of these
patients, and all patients averaged 2.98 fluctuations per 30 days (range 0 to 15.51).
Although most subjects showed a mixture of stool types, they showed distinct individual
patterns which were stable from the first month to the second month. (The third month was
not included in this analysis because many subjects did not complete 3 full months of
uninterrupted data.) As shown in Table 2, the proportion of BMs rated loose/watery
correlated 0.783 between the first and second months, and the proportion of BMs rated hard/
lumpy correlated 0.852 between the first and second months. Symptoms of pain, bloating,
bowel habit dissatisfaction, and life interference were also highly correlated between the
first and the second month.
Distribution of stool consistency ratings across days
The questions used to subtype IBS patients as IBS-D, IBS-C, or IBS-M usually ask about
the proportion of BMs that are loose/watery and the proportion of BMs that are hard/lumpy.
However, this could misrepresent usual bowel habits if loose/watery BMs tend to cluster
together, occurring multiple times a day for a few days with such clusters separated by
several days of normal stools, in contrast to constipation which may be associated with
relatively infrequent hard/lumpy stools. To test this, we calculated the proportion of days
with only normal consistency stools, proportion of days with only loose/watery stools,
proportion of days with only hard/lumpy stools, and the proportion of days with both loose/
watery and hard/lumpy stools. This analysis (Table 3) showed that that day-to-day
variability in stool consistency was similar to BM-to-BM variability. There were only
normal stools on 39.4% of days, only loose/watery stools on 20.1% of days, and only hard/
lumpy stools on 21.8% of days. Both loose/watery and hard/lumpy stools were reported
within the same day on 1.8% of days. There were also 16.9% of days with no BM.
Classification of IBS patients into subtypes by the Rome III Diagnostic Questionnaire
compared to classification based on the daily stool diary
When the Rome questionnaire was used to classify patients, the largest subgroup was IBS-M
(56.2%) and only one patient was classified as IBS-U (see last column of Table 4).
However, when the stool diary was used to classify patients, very few met criteria for IBS-M
(4.6%), and IBS-U became the largest group (35.4% of patients; see first row of Table 4).
This occurred because the Rome questionnaire over-estimated the proportion of BMs that
were loose/watery and the proportion that were hard/lumpy. As a consequence, patients who
were classified as IBS-D by the questionnaire for the most part remained IBS-D or were
reclassified as IBS-U based on the stool diary, and similarly, patients classified as IBS-C by
the questionnaire remained IBS-C or were reclassified as IBS-U. The results of the two
methods of subtyping patients were modestly but significantly related (Chi-square = 19.595;
df = 9; p=.021; Spearman rho=0.265, p<0.001).
Sex and age differences in stool characteristics
Women (n=164) had a higher proportion of BMs rated hard/lumpy compared to the 21 men
(22.5% vs. 11.4%, t=2.727, p=.011), but there were no significant sex differences in the
proportion of BMs that were loose/watery (24.3% vs. 20.0%), the frequency of fluctuations
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between hard/lumpy and loose/watery stools (3.02 vs. 2.90 times per month), or average
stool frequency (1.81 vs. 1.79 stools per day for men vs. women). IBS patients who were
older than the median age of 35 years had significantly more BMs per day than younger
subjects (1.94 vs. 1.64, t=2.185, p=.030), but there were no age related differences in stool
consistency. When the subset of 20 subjects who were aged 55 or older were compared to
younger subjects, no differences in stool consistency or stool frequency were observed. The
frequency of fluctuations between hard/lumpy stools and loose/watery stools was not
correlated with age, sex, overall IBS severity, abdominal pain, bloating, life stress or
psychological symptoms, but a higher frequency of fluctuation was weakly correlated with
poorer IBS-QOL scores (Spearman rho = -0.19, p=0.009).
The association between stool consistency and other bowel symptoms
The symptoms of urgency, pain, and soiling were queried at each BM. When the data were
combined for all IBS subtypes, loose/watery BMs were associated with more symptoms than
hard/lumpy stools for urgency, 79.6% vs. 28.8%, (p<0.0001); for pain and discomfort,
72.9% vs. 52.5%(p<0.0001); and for soiling (incontinence), 5.2% vs. 1.6% (p=0.004).
Other bowel symptoms – abdominal pain, dissatisfaction with bowel function, interference
with life activities, and bloating – were assessed retrospectively for the past 24 hours at the
end of each day rather than at each BM. These symptoms were averaged and compared
across all patients for (a) diarrhea days, defined as days with one or more loose/watery
bowel movements but no hard/lumpy bowel movement; (b) days with normal stool
consistency; and (c) constipation days, defined as days with one or more hard/lumpy bowel
movements but no loose/watery bowel movements (Figure 1). The small number of days on
which both loose/watery and hard/lumpy bowel movements occurred (average of 1.3 days
per subject or 1.8% of all diary days) were excluded from this analysis. Abdominal pain,
bloating, dissatisfaction with bowel function, and interference with life activities were all
rated as significantly more severe during diarrhea days, while constipation days had
significantly less severe symptoms than diarrhea days but more severe symptoms than days
with normal stool consistency.
Association of IBS symptoms with IBS subtypes
Table 5 compares IBS subtypes (subtype classification based on Rome III Diagnostic
Questionnaire) with respect to the average severity of abdominal pain, bloating,
dissatisfaction with bowel habits, and interference with life activities across all days. For all
4 symptoms IBS-C patients reported significantly more symptom severity than IBS-D
patients. This is contrary to what one might expect because loose/watery BMs were more
frequently associated with pain and other symptoms than hard/lumpy stools (Figure 1). It
suggests the hypothesis that symptom distress in IBS-C patients is unrelated to the
occurrence of a BM. To test this hypothesis, we compared the IBS subtypes with respect to
the severity of their IBS symptoms on days when they did not have BMs. Figure 2 supports
this post hoc hypothesis by showing that all 4 symptoms were more severe in IBS-C patients
compared to IBS-D patients on days when no BMs occurred.
Effects of cumulative days without a bowel movement on IBS symptoms in patients with
IBS-C
The observation that on days with no BMs, IBS-C patients have worse symptoms than IBS-
D or IBS-M patients (Figure 2) suggests that, in IBS-C, symptoms may result from the
cumulative distention of the bowel with stool. To test this hypothesis, we performed another
post-hoc test to determine whether the severity of pain and bloating increased with the
cumulative number of days without a BM in patients with IBS-C. The data support this
hypothesis: Average daily pain ratings (0-10 scale) were 4.1 after one day without a BM, 5.0
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after 2 days with no BM, 5.7 after 3 days, 7.5 after 4 days, and 7.2 after 5 days. Day 1 pain
ratings were significantly different from Day 4 and Day 5 by paired t-tests (p<.05).
Similarly, average daily bloating ratings (0-10 scale) were 4.5 on the first day without a BM,
5.6 after 2 days, 5.9 after 3 days, 6.4 after 4 days, and 6.3 after 5 days. Paired t-tests showed
that Day 1 bloating ratings were significantly different from Day 5 (p<.05). The number of
IBS-C patients available for analysis was 16 for Day 2, 12 for Day 3, 6 for Day 4, and 3 for
Day 5.
Differences between retrospective IBS symptom severity scores and diary based symptom
severity scores
Analysis of the diary data showed that the IBS symptoms that make up the IBS Severity
Scale differ significantly between the IBS subtypes, whereas at enrollment when subjects
completed the IBS-SS retrospectively, no such differences between subtypes were found. To
understand this discrepancy a post-hoc analysis was performed. When IBS-SS scores were
computed based on diary responses and compared for the first and second month of diary
days, the correlation between Month 1 and Month 2 was r=0.871 (Table 2). The correlation
between scores on the baseline retrospective IBS-SS questionnaire and the diary based IBS-
SS scores, on the other hand, were lower at r=0.618 for Month 1 and r=0.524 for Month 2.
Discussion
In this diary study, 185 well-characterized IBS patients provided Bristol Stool scores and
other symptom ratings on consecutive BMs for an average of 73 consecutive days, yielding
data on 24,642 stools. The principal findings from this large database were as follows:
1. The majority (58.2%) of all stools are normal in consistency (Bristol Stool Scores
of 3-5).
2. Most IBS patients (77.7%) have both loose/watery stools and hard/lumpy stools,
and they fluctuate between these extremes an average of 3 times per month. These
frequent stool consistency fluctuations occur naturally in all IBS subtypes and are
not due to taking laxatives or antidiarrheal medications.
3. Individual patients have stable distributions of stool types: the proportion of BMs
that are loose/water correlates 0.783 between successive months and the proportion
of BMs that are hard/lumpy correlates 0.852 between months.
4. The Rome III Diagnostic Questionnaire overestimates the frequency of abnormal
stool types but identifies distinct patterns of stool consistency which are correlated
with symptoms.
5. Loose/watery stools are more likely than hard/lumpy stools or normal consistency
stools to be accompanied by symptoms of pain, urgency, and fecal incontinence,
but…
6. Paradoxically, however, patients classified as IBS-C by the Rome criteria report
more abdominal pain, bloating, dissatisfaction with bowel habits, and life
interference than patients meeting Rome III criteria for IBS-D because IBS-C
patients have more symptoms between BMs.
Variability in stool consistency within patients
It is commonly assumed (1) that IBS-C patients have almost exclusively hard/lumpy stools
or a mixture of hard/lumpy stools and stools of normal consistency, and (2) that medications
which cause looser stools are indicated for chronic use in these patients, whereas these
medications are not prescribed to patients with mixed stool types. Similarly, medications
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designed to slow colonic transit and reduce diarrhea are prescribed for chronic use in
patients with IBS-D. However, our data show that 77.7% of IBS patients fluctuate between
loose/watery stools and hard/lumpy stools, with fluctuations occurring an average of 3 times
per month. Only 10% of IBS patients had no loose/watery stools in their diary and only
13.1% had no hard/lumpy stools. These data suggest that daily, fixed-dose drug regimens
which ignore the normal fluctuation of stool consistency may expose patients to an increased
risk of adverse events, and that “as needed” drug dosing regimens should be considered.
Our findings of frequent fluctuation between loose/water stools and hard/lumpy stools in
most IBS patients of all subtypes suggest that fluctuations in stool consistency between
extremes might be a defining general characteristic of IBS. Pimentel et al20 also suggested
that variability in the form and frequency of stools can be used to identify IBS-D patients
and distinguish them from patients with organic causes of diarrhea. However, Pimental used
a question on whether stool form and frequency vary within a day, and we found the co-
occurrence of loose/watery and hard/lumpy stools within the same day to be relatively rare
(1.8% of days).
In view of the frequent fluctuation of bowel habits between stool consistency extremes, one
could question whether it is useful to separate IBS patients into subtypes based on the
predominant stool type rather than assuming that most IBS patients will alternate and
providing instruction for PRN management of both loose/watery and hard/lumpy stool
types. However, we also found that the relative frequencies of hard/lumpy stools and of
loose/watery stools remains relatively constant from month to month; and that there are
significant differences in these relatively stable proportions between IBS-C and IBS-D. This
suggests that separating IBS patients into subtypes based on stool consistency may be
useful. Other investigators have also reported that IBS patients may change the subtype into
which they would be placed by the Rome criteria if assessed over longer intervals of time
such as 6 months to a year6,7. These studies used smaller periods of diary records to assess
stool characteristics and may have underestimated the degree of stability.
Validation of the Rome III criteria for classification of IBS patients into subtypes
The agreement between classification of subtypes based on the retrospective Rome III
Diagnostic Questionnaire and the prospective stool diary was modest (Chi square = 19.60;
df = 9; p=.021). Most of the discrepancies appeared to be due to an over-estimation of the
frequency of loose/watery and of hard/lumpy stools by the Rome questionnaire. This is
shown by the fact that patients classified IBS-D by the Rome questionnaire either remained
in that category when classified based on the stool diary, or they were reclassified as IBS-U
because the proportion of loose/water BMs was below 25%. Similarly, patients classified
IBS-C by the Rome questionnaire either retained this classification or were reclassified IBS-
U. These differences may be largely explained by our use of a response scale from the Rome
III Diagnostic Questionnaire which asked patients whether they had loose/watery stools (or
hard/lumpy stools) “sometimes” or “often” rather than asking them whether this occurred
25% of the time. Patients may have not interpreted “sometimes” as the questionnaire
developers intended. This problem can likely be addressed by the use of an alternative
response scale for the Rome questionnaire.
Relationship between symptoms and stool consistency
We found that loose/watery bowel movements were more likely than hard/lumpy stools or
normal stools to be associated with abdominal pain, urgency, and fecal soiling; and that
patients reported more abdominal pain, bloating, dissatisfaction with bowel habits and
interference with activities of daily life on days when they experienced loose/watery stools
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as compared to days on which they experienced hard/lumpy stools or stools of normal
consistency (Figure 1). This agrees with previous reports9.
However, we found that the amount of symptoms associated with individual bowel
movements is not a good predictor of the overall symptom burden of IBS in general. When
all days are averaged together, patients with IBS-C (i.e., patients with chronic constipation)
have significantly worse abdominal pain, bloating, dissatisfaction with bowel habits, and
interference with life activities than patients with IBS-D (i.e., patients with chronic diarrhea;
see Table 5). This suggests that in IBS-D bowel symptoms are triggered by defecation of
loose/watery BMs whereas in IBS-C, these symptoms are temporally uncorrelated with
defecation and are instead probably related to the chronic distention of the bowel with stool.
This interpretation is supported by two post-hoc analyses: When IBS-C patients were
compared to IBS-D patients on days when no BMs were reported, IBS-C patients had worse
symptoms on those days than patients with IBS-D (Figure 2). Moreover, daily ratings of
pain and bloating become progressively more severe with the cumulative number of days
IBS-C patients have gone without a BM.
These observations may help clinicians to better understand and communicate with their
patients regarding the different effects of diarrhea and constipation on the patient's quality of
life. For patients with diarrhea, it is important to focus on the characteristics of the BMs
such as urgency, frequency, volume, and association with soiling; modifying these stool
characteristics may bring relief. For constipated patients, on the other hand, the patient is
likely to be more concerned by the chronic symptoms of bloating, pain, and tenesmus that
occur throughout the day and that may not show much change with defecation. These
observations on possible different mechanisms for symptoms in IBS-D and IBS-C also have
implications for how one might design outcome assessments that are more sensitive to the
mechanism of action of drugs developed to treat IBS. For patients with IBS-D and for drugs
designed to control diarrhea, it may be appropriate to assess IBS symptoms at the time of
defecation whereas for patients with IBS-C and for drugs designed to relieve constipation, it
may be more appropriate to emphasize daily symptom assessments that are unrelated to
BMs.
Diary assessment
We also made the serendipitous observation that symptom diaries, when collected in a way
that guarantees the symptom reports are made on a daily basis, provide a more sensitive and
reliable method of assessing bowel symptoms than does a retrospective questionnaire.
Greater sensitivity is shown by the fact that the diary data reveal significant differences
between IBS subtypes in their overall IBS-SS scores and in individual IBS symptoms where
as the IBS-SS questionnaire given at baseline showed no differences between IBS subtypes.
Greater reliability of the diary method is shown by the fact that measures of symptom
severity show a stronger correlation between two sequential months of diary recordings
(range, .816 to .862) than between the baseline questionnaire and the diary assessments
(range, .285 to .628). Table 2 also shows that patients overestimate their pain, bloating,
dissatisfaction with bowel habits, and interference with life when they respond on a
questionnaire as compared to when they report these symptoms on a daily diary. As a
consequence, IBS-SS total scores are significantly greater for the retrospective questionnaire
than for the diary method. We infer from these observations that symptom diaries are
superior to retrospective questionnaires as outcome measures in treatment trials. The strong
correlations between the first and second months suggest that one month of diary data will
be adequate for most purposes.
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Study strengths and limitations
Other studies have used daily symptom ratings to investigate patterns of stool consistency.
However, our methodology has several advantages over comparable prior work: Previous
studies have generally relied on paper diaries returned to the investigator at intervals of a
few weeks. Paper diaries collected in this way are known to be vulnerable to non-adherence
and recollection bias, because many subjects wait until it is time to return the diaries to the
investigator and fill out several days retrospectively from memory or leave some days
blank21, 22. By contrast, we required patients to report on their bowel symptoms each day
via an internet website, reinforced daily completion via telephone and email contact the next
day for any missing days, and used only continuous series of diary records for analysis.
Additionally, the length of the diary records we collected averaged 73 days in contrast to 7
days23, 24, 14 days7, or 28 days6 in previous studies, providing a broader picture of symptom
variation. The reliability of the assessment of symptoms and stool consistency is reflected by
the very high degree of comparability of Month 1 and Month 2 data (Table 4).
The limitations of our study include a relatively small group of only 23 IBS-C patients. This
small sub-sample limited the statistical power to assess the effects of cumulative days
without a BM on symptoms of pain and bloating. A second limitation is that our sample was
younger than usually encountered in studies of IBS (median age of 37 compared to 51 years
in other studies25). This age difference likely reflects the requirement that patients should
have daily internet access in order to participate. Lastly, we used the standard response scale
in the Rome III Diagnostic Questionnaire which asks patients whether they have hard/lumpy
stools (or loose/watery stools) “Never or rarely”, “Sometimes”, “Often”, etc. instead of the
alternative response scales which ask them whether they have hard/lumpy stools “About
25% of the time”, “About 50% of the time”, etc. This likely contributed to the observed
tendency for the Rome III Diagnostic Questionnaire to overestimate the frequency of hard/
lumpy and loose/watery stools when a response of “sometimes” was equated with 25% of
the time. However, the method we used is the current standard form of the Rome
questionnaire, and our finding that it substantially over-estimates the amount of hard and
loose stools suggests that alternative wording may be needed to subtype IBS.
Summary
We made three key observations that have implications for clinical practice: First, the
finding that ¾ of IBS patients fluctuate between the extremes of loose/watery stools and
hard/lumpy stools suggests that medications which target diarrhea or constipation may
produce fewer side-effects and greater patient satisfaction if dosed “as needed” rather than
on a fixed dose. Second, we found that different mechanisms appear to be responsible for
pain and other bowel symptoms in diarrhea (defecation-related sensations) vs. constipation
(cumulative distention of the bowel). This insight may improve our ability to communicate
with patients about the causes of their discomfort and the goals of treatment. Third, we have
shown that symptom diaries, collected by internet to guarantee timely reporting, are more
sensitive and reliable than questionnaires or interviews for evaluating symptom severity and
response to treatment.
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What is Current Knowledge
• IBS patients are sub-classified based on the average frequency of loose or
watery stools and the average frequency of hard or lumpy stools.
• Classification by predominant stool consistency is critical to management
because current IBS drugs were designed to treat either constipation or diarrhea,
and there is a risk of adverse events if they are given to patients with the wrong
stool consistency.
• Reports are inconsistent on the relationship between stool consistency and
abdominal pain.
What is New Here
• Approximately 78% of IBS patients of all subtypes fluctuate between the
extremes of loose/watery stools and hard/lumpy stools; this suggests that IBS
drugs might produce better outcomes and fewer side effects if prescribed “as
needed” rather than on a fixed dose.
• Abdominal pain appears to be caused by different pathophysiological
mechanisms in IBS-D and IBS-C: in IBS-D, pain is associated with the passage
of a loose/watery stool whereas in IBS-C, pain increases with distention from
cumulative days without a stool.
• Daily symptom monitoring through the internet is more sensitive and reliable
than a questionnaire for assessing individual differences in symptom severity.
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Comparison of bowel symptoms of IBS patients on days with diarrhea, constipation or
normal stool consistency. Means and standard errors are shown. All paired comparisons
between Diarrhea Days, Normal Stool Days, and Constipation Days are significant at p<.05.
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Symptom severity in different IBS subtypes on days with no bowel movements. Brackets
show comparisons that are significant at p<.05.
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Table 1
Demographic characteristics and symptoms at enrollment.
Total sample (N=185) IBS-D (n=59) IBS-M (n=102) IBS-C (n=23)
Age; mean (S.D.) 36.59 (12.16) 39.47 (11.71) 35.63 (12.36) 33.43 (11.43)
Gender (% female) 88.60% 77.97%* 94.12% 91.30%
Race (% white) 94.10% 94.90% 92.20% 100%
Overall IBS Severity; mean(S.D.) 258.04 (96.91) 248.64 (106.34) 260.29 (88.34) 272.17 (109.54)
Abdominal pain severity; mean (S.D.) 5.17 (2.32) 4.93 (2.46) 5.26 (2.23) 5.39 (2.37)
Bloating severity; mean (S.D.) 4.56 (2.90) 4.41 (2.96) 4.48 (2.74) 5.30 (3.47)
Dissatisfaction with bowel habits; mean (S.D.) 6.29 (2.71) 6.14 (2.76) 6.49 (2.57) 5.78 (3.19)
Interference of bowel symptoms with life activities mean
(S.D.)
4.82 (2.89) 4.78 (3.14) 4.91 (2.66) 4.52 (3.26)
Health-related quality of life score - IBS-QOL; mean (S.D.) 58.66 (18.79) 59.69 (19.89) 57.24 (18.09) 62.34 (18.80)
Psychological Distress BSI-18 Global Symptom Index
scale; mean T-score (S.D.)
56.01 (10.40) 57.58 (9.15) 59.17 (9.37) 57.28 (9.60)
Somatization Scale of BSI- 18; mean T-score (S.D.) 58.13 (8.68) 56.59 (9.40) 58.64 (7.90) 59.78 (9.84)
Life stress in past 10 days - 0-10 ratings; mean (S.D.) 4.86 (2.86) 4.24 (3.10) 5.14 (2.58) 5.22 (3.22)
*
IBS-D less than IBS-C or IBS-M, p<.05.
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Table 5
Overall Association of IBS Subtype with Symptoms of IBS.
Symptoms All IBS IBS-D IBS-M IBS-C
Abdominal pain 3.44 (1.91) 2.91 (1.74) 3.51 (1.77) 4.52 (2.47)D
Bloating 3.80 (2.17) 3.30 (1.92) 3.87 (2.10) 4.79 (2.79)D
Dissatisfaction with bowel habits 4.55 (2.01) 3.80 (1.95) 4.74 (1.93 5.65 (1.97)D,M
Interference with life activities 2.97 (1.80) 2.57 (1.61) 3.03 (1.72) 3.71 (2.40)D
D
Significantly different from IBS-D;
M
Significantly different from IBS-M.
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